Axonics Modulation Technologies is a medical devices business based in the US. Axonics Modulation Technologies shares (AXNX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $70.98 – the same closing value as a week prior. Axonics Modulation Technologies employs 797 staff and has a trailing 12-month revenue of around $431.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $70.98 |
|---|---|
| 52-week range | $55.09 - $71.05 |
| 50-day moving average | $69.87 |
| 200-day moving average | $68.37 |
| Wall St. target price | $72.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $70.98 from 2024-11-14
| 1 week (2024-11-14) | 70.98 |
|---|---|
| 1 month (2024-10-24) | 1.00% |
| 3 months (2024-08-23) | 2.94% |
| 6 months (2024-05-23) | 5.42% |
| 1 year (2023-11-22) | 22.74% |
|---|---|
| 2 years (2022-11-23) | 9.27% |
| 3 years (2021-11-23) | 19.19% |
| 5 years (2019-11-22) | 220.89% |
Valuing Axonics Modulation Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Axonics Modulation Technologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Axonics Modulation Technologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.3 million.
The EBITDA is a measure of a Axonics Modulation Technologies's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $431.9 million |
|---|---|
| Gross profit TTM | $197.7 million |
| Return on assets TTM | -0.63% |
| Return on equity TTM | -0.89% |
| Profit margin | -1.31% |
| Book value | $13.00 |
| Market Capitalization | $3.6 billion |
TTM: trailing 12 months
We're not expecting Axonics Modulation Technologies to pay a dividend over the next 12 months.
Over the last 12 months, Axonics Modulation Technologies's shares have ranged in value from as little as $55.09 up to $71.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axonics Modulation Technologies's is 0.827. This would suggest that Axonics Modulation Technologies's shares are less volatile than average (for this exchange).
Axonics, Inc. , a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.